ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

Zacks
Öffnen unter Zacks
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

ADMA Biologics’ ADMA shares have gained 20.9% over the past week against the industry’s decline of 0.4%.  

The stock rallied after the company reported better-than-expected results for the third quarter on Nov. 4, 2026.

ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).

Year to date, shares of the company have gained 29.5% compared with the industry’s growth of 6.3%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame.

ADMA Outperforms Industry, Sector and S&P 500 Index

Zacks Investment Research
Image Source: Zacks Investment Research

Robust demand for lead drug Asceniv maintains momentum for the company amid declining Bivigam sales.

ADMA reiterated its full-year 2026 revenue expectation of at least $530 million. The outlook reflects continued Asceniv momentum alongside conservative assumptions about competition in the standard immune globulin market.

The company raised its minimum adjusted net income outlook to $180 million and minimum adjusted EBITDA outlook to $275 million. In the second quarter, management had projected adjusted net income of $170-$200 million and adjusted EBITDA of $265-$300 million.

Against this backdrop, a closer examination of ADMA’s key strengths and potential challenges is warranted to better assess the stock’s investment appeal.

Asceniv Fuels ADMA’s Top-Line Growth

Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies.

Asceniv remained the key contributor to ADMA’s revenue performance in the third quarter, while the company’s other product lines trended in the opposite direction.

Asceniv’s revenues surged 31% year over year and 21% sequentially, driven by increased physician adoption, higher new patient starts and stronger end-user utilization. Favorable demand trends have continued into the fourth quarter, underscoring the product’s sustained growth momentum and substantial untapped market opportunity.

ADMA plans to present an analysis of 127 medically complex patients with primary immunodeficiency treated with Asceniv at the American College of Allergy, Asthma and Immunology (“ACAAI”) annual conference shortly. Most patients had previously received other immune globulin therapies.

The analysis showed statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, and the use of oral antibiotics and corticosteroids following the initiation of Asceniv treatment. These findings support Asceniv’s positioning as a treatment option for later-line, refractory and medically complex PI patients.

Bivigam Sales Decline But Show Signs of Stabilization

Bivigam generated third-quarter revenues of $15.4 million, down from $19.4 million in the second quarter, reflecting continued competitive pricing and channel inventory pressures in the standard immunoglobulin (IG) market. Sales declined 47.1% in the first nine months of 2026.

Nonetheless, underlying end-user utilization showed encouraging signs of stabilization heading into the fourth quarter. ADMA continues to prioritize disciplined commercial execution rather than matching aggressive competitor discounting and rebate practices.

ADMA’s Valuation & Estimates

Going by the price/sales ratio, ADMA’s shares currently trade at 4.56x forward sales, higher than its mean of 3.78x and the industry’s 2x.

Zacks Investment Research
Image Source: Zacks Investment Research

Estimate Movement

The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved north to 82 cents from 78 cents in the past seven days, while that for 2027 EPS has inched up to 86 cents from 85 cents in the same time frame.

Zacks Investment Research
Image Source: Zacks Investment Research

Stay Invested in ADMA Stock for Now

ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, has effectively navigated competitive pressures in the immunoglobulin (IG) market throughout 2026.

Strong growth in Asceniv sales, expanding physician adoption and encouraging real-world clinical evidence support its revenue growth prospects.

The company also raised its minimum adjusted net income and EBITDA outlook for 2026, while positive earnings estimate revisions reflect improving analyst sentiment.

However, continued weakness in Bivigam sales, competitive pricing and channel inventory pressures in the standard IG market remain concerns. Moreover, the stock’s sharp recent rally and premium valuation relative to its historical average and industry limit the upside from current levels.

While ADMA’s growth prospects remain encouraging, these risks warrant a balanced approach. Existing investors can continue to hold the stock, while new investors may wait for a better entry point.

ADMA currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
 
Grifols, S.A. (GRFS): Free Stock Analysis Report
 
Takeda Pharmaceutical Co. (TAK): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research